A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

MLN2704 is an antibody-chemotherapeutic conjugate designed to target prostate-specific membrane antigen (PSMA). PSMA is a transmembrane receptor whose expression is largely restricted to prostatic epithelium and prostate cancer cells with its expression level increasing during the progression of mal...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2004-11, Vol.64 (21), p.7995-8001
Main Authors: HENRY, Michael D, SHENGHUA WEN, SILVA, Matthew D, CHANDRA, Sudeep, MILTON, Mark, WORLAND, Peter J
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - therapeutic use
Antigens, Surface
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Bone Neoplasms - secondary
Glutamate Carboxypeptidase II - antagonists & inhibitors
Humans
Immunotoxins - therapeutic use
Male
Maytansine - analogs & derivatives
Maytansine - therapeutic use
Medical sciences
Mice
Neoplasm Transplantation
Pharmacology. Drug treatments
Prostatic Neoplasms - therapy
Transplantation, Heterologous
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MLN2704 is an antibody-chemotherapeutic conjugate designed to target prostate-specific membrane antigen (PSMA). PSMA is a transmembrane receptor whose expression is largely restricted to prostatic epithelium and prostate cancer cells with its expression level increasing during the progression of malignancy. MLN2704 consists of a de-immunized, monoclonal antibody that is specific for PSMA conjugated to drug maytansinoid 1 (DM1), a microtubule-depolymerizing compound. After antibody binding to PSMA and the subsequent cellular internalization of this complex, DM1 is released leading to cell death. MLN2704 has an approximate half-life of 39 hours in scid mice bearing CWR22 tumor tissue, and the antibody effectively penetrates xenograft tumor tissue. Optimization of dosage and schedule of MLN2704 administration defined interdependency between these conditions that maximized efficacy with no apparent toxicity. Tumor growth delays of approximately 100 days could be achieved on the optimized schedule of one dose of 60 mg/kg MLN2704 every 14 days for five doses (q14dx5). The unconjugated antibody (MLN591) demonstrated essentially no antitumor activity and DM1 alone or a non-PSMA targeted antibody-DM1 conjugate was only weakly active. Furthermore, we show that MLN2704 is active in a novel model of osteoblastic prostate cancer metastasis.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-04-1722